Last reviewed · How we verify
NCT04551144
Effect of Transgender Therapy on Muscle, Fat and Tissue Receptors
trial testing testosterone cypionate in Gender Incongruence in 4 participants. Terminated before completion.
18 January 2023
Quick facts
| Lead sponsor | St. Louis University |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 4 |
| Start date | 6 October 2020 |
| Primary completion | 18 January 2023 |
| Estimated completion | 18 January 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- testosterone cypionate — full drug profile →
- Estradiol Valerate (ESTRADIOL VALERATE) — full drug profile →
Conditions studied
- Gender Incongruence — all drugs for Gender Incongruence →
- Transgenderism — all drugs for Transgenderism →
Sponsor
St. Louis University
Who can join
Adults 18 to 50, any sex, with Gender Incongruence or Transgenderism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this research is to find out if hormone therapy in transgender subjects' changes hormone receptors in blood, muscle and fat; fat production; muscle production; and inflammation processes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04551144
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of testosterone cypionate
Trials testing the same drug.
- NCT06059118 — Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer · Phase 2 · recruiting
- NCT02995330 — Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer · Phase 1 · terminated
Other recruiting trials for Gender Incongruence
Currently open trials in the same condition.
- NCT07187947 — Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway · recruiting
- NCT05318755 — China Gender-affirming Hormone Therapy Study · recruiting
- NCT06953908 — The Copenhagen Gender Identity Cohort · recruiting
- NCT04028219 — Transgender In Transition · recruiting
Other St. Louis University trials
Trials by the same sponsor.
- NCT07024940 — Short-term Effects of Caffeine and a Multi-ingredient Pre-workout on Exercise Performance · NA · recruiting
- NCT06859528 — Step Up to PD: A Community-based Walking Program for People With Parkinson's Disease · NA · recruiting
- NCT04158037 — Don't Go There: A Geospatial mHealth App for Gambling Disorder · NA · withdrawn
- NCT05406310 — Clinical Outcomes of Persistent Atrial Fibrillation Ablation Using Ablation Index-guided Radiofrequency Catheter Ablatio · withdrawn
- NCT05854836 — Preconception Intervention for Incarcerated Women With Substance Use · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04551144 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by St. Louis University
- Last refreshed: 8 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04551144.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing